ReCode Therapeutics
PrivateLast Round
Grant
Sep 29, 2025
Est. Valuation
$372M
Total Funding Raised
$551M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ReCode Therapeutics is a biotechnology company that specializes in targeted delivery technology utilizing lipid nanoparticles to administer genetic therapies for patients with rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ReCode Therapeutics Comparables
Compare ReCode Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ethris | 84% | |
| Arcturus Therapeutics Holdings Inc. | 83% | |
| Spirovant Sciences | 81% | |
ReCode Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 29, 2025 | ||||
| Grant | Nov 18, 2024 | ||||
| Series B Extension | Sep 19, 2023 | ||||
| Grant | Jan 10, 2023 | ||||
| Series B Extension | Jun 29, 2022 | ||||
Series B | Oct 21, 2021 |
Key People
Founding team and executive leadership
ReCode Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B, Series B Extension |
| MPM Capital | Series A, Series B, Series B Extension |
| Bioluminescence Ventures | Series B, Series B Extension |
| Vida Ventures | Series A, Series B, Series B Extension |
| MPM BioImpact | Series A, Series B |
| Osage University Partners | Series A, Series B, Series B Extension |
| OrbiMed | Series A, Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 29, 2025
Secured $3M in grant funding.
- Mar 25, 2025
Recognized by San Francisco Business Times and Silicon Valley Business Journal.
ReCode Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ReCode Therapeutics's valuation, stock price, and market status.